Probing Dual Covalent Irreversible Inhibition of EGFR/FGFR4 by Electrophilic-Based Natural Compounds to Overcome Resistance and Enhance Combination Therapeutic Potentials and Management of Hepatocellular Carcinoma (HCC)-Reference-Cited by-同舟云学术

Probing Dual Covalent Irreversible Inhibition of EGFR/FGFR4 by Electrophilic-Based Natural Compounds to Overcome Resistance and Enhance Combination Therapeutic Potentials and Management of Hepatocellular Carcinoma (HCC)

Published:2024-07-09 Issue:4 Volume:43 Page:793-804
ISSN:1572-3887
Container-title:The Protein Journal
language:en
Short-container-title:Protein J

Author:

Xue Huimin,Chen Peng,Jiao Jingyi,Zhu Xiaojun

Funder

Doctoral Research Project of Affiliated Hospital of Nantong University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10930-024-10211-2.pdf

Reference41 articles.

1. Villanueva A (2019) Hepatocellular Carcinoma. N Engl J Med 380:1450–1462

2. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19:940–952

3. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492–2502

4. Sangro B, Harding JJ, Johnson M, Palmer DH, Edeline J, Abou-Alfa GK et al (2021) A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). https://doi.org/101200/JCO2021393_supplTPS349. ;39 3_suppl:TPS349–TPS349

5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390